362 related articles for article (PubMed ID: 11828341)
21. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease.
Sakuraba H; Oshima A; Fukuhara Y; Shimmoto M; Nagao Y; Bishop DF; Desnick RJ; Suzuki Y
Am J Hum Genet; 1990 Nov; 47(5):784-9. PubMed ID: 2171331
[TBL] [Abstract][Full Text] [Related]
22. Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.
Dai X; Zong X; Pan X; Lu W; Jiang GR; Lin F
Orphanet J Rare Dis; 2022 Jun; 17(1):237. PubMed ID: 35725559
[TBL] [Abstract][Full Text] [Related]
23. Mutation analysis of alpha-galactosidase a gene in Hungarian Fabry patients.
László A; Török L; Raffai S; Török E; Sallay E; Endreffy E; Morvai L; van Amstel JK
Ideggyogy Sz; 2012 Jan; 65(1-2):35-9. PubMed ID: 22338844
[TBL] [Abstract][Full Text] [Related]
24. Splicing of a myosin phosphatase targeting subunit 1 alternative exon is regulated by intronic cis-elements and a novel bipartite exonic enhancer/silencer element.
Dirksen WP; Mohamed SA; Fisher SA
J Biol Chem; 2003 Mar; 278(11):9722-32. PubMed ID: 12509424
[TBL] [Abstract][Full Text] [Related]
25. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
26. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
[TBL] [Abstract][Full Text] [Related]
27. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation of exonic regulatory elements for muscle-specific alternative splicing during myogenesis and cardiogenesis.
Ichida M; Hakamata Y; Hayakawa M; Ueno E; Ikeda U; Shimada K; Hamamoto T; Kagawa Y; Endo H
J Biol Chem; 2000 May; 275(21):15992-6001. PubMed ID: 10821853
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
Germain DP; Poenaru L
Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
[TBL] [Abstract][Full Text] [Related]
30. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.
Chien YH; Lee NC; Chiang SC; Desnick RJ; Hwu WL
Mol Med; 2012 Jul; 18(1):780-4. PubMed ID: 22437327
[TBL] [Abstract][Full Text] [Related]
31. A 3' splice site consensus sequence mutation in the intron 3 of the alpha-galactosidase A gene in a patient with Fabry disease.
Yokoi T; Shinoda K; Ohno I; Kato K; Miyawaki T; Taniguchi N
Jinrui Idengaku Zasshi; 1991 Sep; 36(3):245-50. PubMed ID: 1753437
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene.
Eng CM; Niehaus DJ; Enriquez AL; Burgert TS; Ludman MD; Desnick RJ
Hum Mol Genet; 1994 Oct; 3(10):1795-9. PubMed ID: 7531540
[TBL] [Abstract][Full Text] [Related]
33. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
[TBL] [Abstract][Full Text] [Related]
34. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
35. Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease.
Ishii S; Sakuraba H; Suzuki Y
Hum Genet; 1992 Apr; 89(1):29-32. PubMed ID: 1315715
[TBL] [Abstract][Full Text] [Related]
36. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
[TBL] [Abstract][Full Text] [Related]
37. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene.
Aretz S; Uhlhaas S; Sun Y; Pagenstecher C; Mangold E; Caspari R; Möslein G; Schulmann K; Propping P; Friedl W
Hum Mutat; 2004 Nov; 24(5):370-80. PubMed ID: 15459959
[TBL] [Abstract][Full Text] [Related]
38. Localization of an exonic splicing enhancer responsible for mammalian natural trans-splicing.
Caudevilla C; Codony C; Serra D; Plasencia G; Román R; Graessmann A; Asins G; Bach-Elias M; Hegardt FG
Nucleic Acids Res; 2001 Jul; 29(14):3108-15. PubMed ID: 11452036
[TBL] [Abstract][Full Text] [Related]
39. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
40. Functional studies of new GLA gene mutations leading to conformational Fabry disease.
Filoni C; Caciotti A; Carraresi L; Cavicchi C; Parini R; Antuzzi D; Zampetti A; Feriozzi S; Poisetti P; Garman SC; Guerrini R; Zammarchi E; Donati MA; Morrone A
Biochim Biophys Acta; 2010 Feb; 1802(2):247-52. PubMed ID: 19941952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
